Key result
Sequential ticagrelor and prasugrel therapy fails to prevent recurrent stent thrombosis requiring CABG after STEMI.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case highlights the rare but severe occurrence of recurrent stent thrombosis in a STEMI patient despite the sequential use of multiple potent P2Y12 inhibitors and GP IIb/IIIa inhibitors, necessitating surgical revascularization.
A 54-year-old Kuwaiti male presented an inferior wall ST elevation myocardial infarction (STEMI). Clopidogrel 600mg was administered by the first medical contact and Ticagrelor 180 mg with intravenous (IV) glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor infusion for 24 hours after primary percutaneous intervention. Despite this, several episodes of stent thrombosis occurred during the subsequent days. Because of this, Ticagrelor was switched to Pasugrel and the patient was loaded with 60mg of Pasugrel. Unfortunately, further in-stent thrombosis occurred and therefore, after discussion, coronary artery bypass graft surgery was performed.
No takes yet. Share an insight, caveat, or question.
Al‐Jarallah et al. (2019) conducted a case report in ST elevation myocardial infarction (STEMI) (n=1). Ticagrelor and Pasugrel was evaluated on Stent thrombosis. Sequential treatment with ticagrelor and pasugrel failed to prevent recurrent stent thrombosis in a 54-year-old STEMI patient, ultimately requiring coronary artery bypass graft surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: